Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Cyclophilin A, an immunophilin is secreted from human monocytes activated by high glucose. Given its role as an inflammatory mediator of vascular tissue damage associated with inflammation and oxidative stress, we examined plasma levels of cyclophilin A in normal healthy volunteers and patients with type 2 diabetes (DM), with or without coronary artery disease (CAD). METHODS: Study subjects comprised of 212 patients with DM and CAD,101 patients with diabetes, 122 patients with CAD and 121 normal healthy volunteers. Diabetes was assessed by HbA1c levels while coronary artery disease was established by a positive treadmill test and/or coronary angiography. Plasma cyclophilin A was measured using a cyclophilin A ELISA Kit. Relationship of plasma cyclophilin A levels with blood markers of type 2 diabetes, blood lipid levels and medication for diabetes and coronary artery disease were also explored. RESULTS: Plasma Cyclophilin levels were higher in diabetes patients with or without CAD compared to normal subjects (P < 0.001). Age, fasting blood sugar levels and HbA1C levels were positively associated with increased plasma cyclophilin. Patients using metformin had reduced levels of plasma cyclophilin (p < 0.001).Serum levels of total cholesterol, LDL cholesterol and triglycerides had no significant association with plasma cyclophilin levels. In patients with increased serum CRP levels, plasma cyclophilin A was also elevated (p = 0.016). Prevalence odds for DM, DM + CAD and CAD are higher in those with high cyclophilin values, compared to those with lower values, after adjusting for age and sex, indicating strong association of high cyclophilin values with diabetes and vascular disease. CONCLUSIONS/INTERPRETATIONS: Our study demonstrates that patients with type 2 diabetes have higher circulating levels of cyclophilin A than the normal population. Plasma cyclophilin levels were increased in patients with diabetes and coronary artery disease suggesting a role of this protein in accelerating vascular disease in type 2 diabetes. Considering the evidence that Cyclophilin A is an inflammatory mediator in atherogenesis, the mechanistic role of cyclophilin A in diabetic vascular disease progression deserves detailed investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tracy, R. P., Lemaitre, R. N., Psaty, B. M., Ives, D. G., Evans, R. W., Cushman, M., Meilahn, E. N., & Kuller, L. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.6.1121 · Cited by 836 · cited 1×
“CRP, an acute phase reactant has been developed as a surrogate marker of inflammatory mediators in coronary artery disease and diabetes [15–18].”
C-Reactive Protein: A Simple Test to Help Predict Risk of Heart Attack and Stroke
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000093381.57779.67 · Cited by 448 · cited 2×
“Association of C reactive protein with cyclophilin A levels It is well recognized that patients with low serum CRP (<1 mg/L) are at low risk and those with higher CRP (>1 mg/L) are at moderate or high risk for future cardiovascular events [5].”
OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects
Moreno-Navarrete, J. M., Ortega, F. J., Rodríguez-Hermosa, J.-I., Sabater, M., Pardo, G., Ricart, W., & Fernández-Real, J. M. (2011) · Diabetes · doi:10.2337/db10-0805 · Cited by 100
Cited by
BERTUCCELLI, G., ZERBINATI, N., MARCELLINO, M., NANDA KUMAR, N. S., HE, F., TSEPAKOLENKO, V., CERVI, J., LORENZETTI, A., & MAROTTA, F. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3011 · Cited by 36
“Cyclophilin A (CyPA), a member of the immunophilin family, has been recently found to play an important role in impairing skin DNA repair mechanisms (17), while also affecting systemic oxidative stress‑inflammatory response (18,19).”
The aged hematopoietic system promotes hippocampal‐dependent cognitive decline
Smith, L. K., Verovskaya, E., Bieri, G., Horowitz, A. M., von Ungern‐Sternberg, S. N. I., Lin, K., Seizer, P., Passegué, E., & Villeda, S. A. (2020) · Aging Cell · doi:10.1111/acel.13192 · Cited by 31
“In these studies, CyPA plasma levels were also found to be elevated with aging (Ohtsuki et al., 2017; Ramachandran et al., 2014; Satoh et al., 2013).”
BackgroundAnandan, V., Thulaseedharan, T., Suresh Kumar, A., Chandran Latha, K., Revikumar, A., Mullasari, A., Kartha, C. C., Jaleel, A., & Ramachandran, S. (2021) · Cells · doi:10.3390/cells10123598 · Cited by 18
Self-citation
Metadata
- Authors
- Ramachandran, S., Venugopal, A., Kutty, V. R., A, V., G, D., Chitrasree, V, Mullassari, A., Pratapchandran, N. S., Santosh, K. R., Pillai, M. R., & Kartha, C. C.
- Venue
- Cardiovascular Diabetology
- Published
- 2014-02-07
- Volume
- 13
- Issue
- 1
- Pages
- 38-38
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W2111932825
- Cited by
- 82
- References
- 3
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. https://app.cochat.ai/papers/10.1186/1475-2840-13-38
- The paper
- Ramachandran, S., Venugopal, A., Kutty, V. R., A, V., G, D., Chitrasree, V, Mullassari, A., Pratapchandran, N. S., Santosh, K. R., Pillai, M. R., & Kartha, C. C. (2014). Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-13-38
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.